<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730275</url>
  </required_header>
  <id_info>
    <org_study_id>0431-081</org_study_id>
    <secondary_id>2008_540</secondary_id>
    <nct_id>NCT00730275</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)</brief_title>
  <official_title>A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to
      17 year old diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2008</start_date>
  <completion_date type="Actual">February 14, 2011</completion_date>
  <primary_completion_date type="Actual">December 30, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>Pre-study through 10 to 14 days following administration of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin</measure>
    <time_frame>Pre-dose through 72 hours post-dose</time_frame>
    <description>Serum samples were used to determine the AUC from time 0 to infinity for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin</measure>
    <time_frame>Pre-dose through 72 hours post-dose</time_frame>
    <description>Serum samples were used to determine the Cmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin</measure>
    <time_frame>Pre-dose through 72 hours post-dose</time_frame>
    <description>Serum samples were used to determine the Tmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin</measure>
    <time_frame>Pre-dose through 72 hours post-dose</time_frame>
    <description>Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo</measure>
    <time_frame>Pre-dose through 24 hours post-dose</time_frame>
    <description>Plasma DPP-4 activity was analyzed using the 24-hour weighted average inhibition (WAI) and percent inhibition at 24 hours post-dose.
WAI was defined as the AUC of inhibition divided by the length of the post-dose time interval. Positive values of WAI represent a decrease in DPP-4 activity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were randomized to sitagliptin 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were randomized to sitagliptin 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were randomized to a single dose of sitagliptin 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to sitagliptin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin phosphate</intervention_name>
    <description>Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.</description>
    <arm_group_label>Sitagliptin 50 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Sitagliptin 200 mg</arm_group_label>
    <other_name>MK-0431</other_name>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: matching placebo</intervention_name>
    <description>Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.</description>
    <arm_group_label>Placebo to sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females who are 10 - 17 years of age

          -  History of type 2 diabetes

          -  Nonsmoker

          -  No clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes

        Exclusion Criteria:

          -  History of diabetic ketoacidosis

          -  History of stroke, chronic seizures or major neurological disorder

          -  Consumes alcohol

          -  Consume more than 6 servings (1 serving is approximately equivalent to 120 mg of
             caffeine) of coffee, tea, cola or other beverages containing caffeine per day

          -  Unable to swallow tablets

          -  Has had surgery, donated or lost 1 unit of blood, or participated in another
             investigational study within a minimum of 4 weeks prior to starting the study

          -  History of multiple and/or severe allergies or has had an allergic reaction to or
             significant intolerability to prescription or non-prescription drugs or food

          -  Currently a regular user of any illicit drugs or has a history of drug or alcohol
             abuse

          -  History of clinically significant endocrine, gastrointestinal,

        cardiovascular, hematological, hepatic, immunological, renal, respiratory, or

        genitourinary abnormalities or diseases

          -  Has an estimated creatinine clearance of less than or equal to 80 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>December 21, 2011</results_first_submitted>
  <results_first_submitted_qc>December 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2012</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 50 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin 100 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
        </group>
        <group group_id="P3">
          <title>Sitagliptin 200 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants who received a single oral dose of a matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 50 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin 100 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
        </group>
        <group group_id="B3">
          <title>Sitagliptin 200 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants who received a single oral dose of a matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="2.52"/>
                    <measurement group_id="B2" value="14.3" spread="1.41"/>
                    <measurement group_id="B3" value="14.8" spread="1.75"/>
                    <measurement group_id="B4" value="14.1" spread="2.26"/>
                    <measurement group_id="B5" value="14.3" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One Adverse Event</title>
        <time_frame>Pre-study through 10 to 14 days following administration of study drug</time_frame>
        <population>All enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 100 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 200 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants who received a single oral dose of a matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Adverse Event</title>
          <population>All enrolled participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin</title>
        <description>Serum samples were used to determine the AUC from time 0 to infinity for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
        <time_frame>Pre-dose through 72 hours post-dose</time_frame>
        <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 100 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 200 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin</title>
          <description>Serum samples were used to determine the AUC from time 0 to infinity for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
          <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
          <units>nM*hour</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3438" lower_limit="2881" upper_limit="4103"/>
                    <measurement group_id="O2" value="5869" lower_limit="4918" upper_limit="7003"/>
                    <measurement group_id="O3" value="12965" lower_limit="10749" upper_limit="15638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin</title>
        <description>Serum samples were used to determine the Cmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
        <time_frame>Pre-dose through 72 hours post-dose</time_frame>
        <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 100 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 200 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin</title>
          <description>Serum samples were used to determine the Cmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
          <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366" lower_limit="288" upper_limit="464"/>
                    <measurement group_id="O2" value="666" lower_limit="526" upper_limit="845"/>
                    <measurement group_id="O3" value="1876" lower_limit="1458" upper_limit="2413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin</title>
        <description>Serum samples were used to determine the Tmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
        <time_frame>Pre-dose through 72 hours post-dose</time_frame>
        <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 100 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 200 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin</title>
          <description>Serum samples were used to determine the Tmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
          <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.5" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="4.5"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin</title>
        <description>Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
        <time_frame>Pre-dose through 72 hours post-dose</time_frame>
        <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 100 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 200 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin</title>
          <description>Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.</description>
          <population>All participants who received a single dose of sitagliptin 50 mg, 100 mg, or 200 mg.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="1.7"/>
                    <measurement group_id="O2" value="11.2" spread="2.1"/>
                    <measurement group_id="O3" value="11.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo</title>
        <description>Plasma DPP-4 activity was analyzed using the 24-hour weighted average inhibition (WAI) and percent inhibition at 24 hours post-dose.
WAI was defined as the AUC of inhibition divided by the length of the post-dose time interval. Positive values of WAI represent a decrease in DPP-4 activity.</description>
        <time_frame>Pre-dose through 24 hours post-dose</time_frame>
        <population>All participants who received a single dose of sitagliptin or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 50 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 100 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
          </group>
          <group group_id="O3">
            <title>Sitagliptin 200 mg</title>
            <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants who received a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo</title>
          <description>Plasma DPP-4 activity was analyzed using the 24-hour weighted average inhibition (WAI) and percent inhibition at 24 hours post-dose.
WAI was defined as the AUC of inhibition divided by the length of the post-dose time interval. Positive values of WAI represent a decrease in DPP-4 activity.</description>
          <population>All participants who received a single dose of sitagliptin or placebo.</population>
          <units>Percent inhibition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-hour WAI of DPP-4 activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.98" lower_limit="70.59" upper_limit="76.99"/>
                    <measurement group_id="O2" value="80.53" lower_limit="77.98" upper_limit="82.78"/>
                    <measurement group_id="O3" value="87.96" lower_limit="86.29" upper_limit="89.43"/>
                    <measurement group_id="O4" value="6.76" lower_limit="-6.21" upper_limit="18.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DDP-4 activity at 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.98" lower_limit="46.74" upper_limit="60.24"/>
                    <measurement group_id="O2" value="62.78" lower_limit="56.92" upper_limit="67.84"/>
                    <measurement group_id="O3" value="75.76" lower_limit="71.70" upper_limit="79.24"/>
                    <measurement group_id="O4" value="3.57" lower_limit="-12.60" upper_limit="17.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 50 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 50 mg.</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin 100 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 100 mg.</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin 200 mg</title>
          <description>Participants who received a single oral dose of sitagliptin 200 mg.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants who received a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharpe &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

